Month: November 2024

DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Metastatic Breast Cancer pipeline landscape. It covers the Metastatic Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Metastatic Breast Cancer Research. Learn more about our innovative pipeline today! @ Metastatic Breast Cancer Pipeline Outlook

Key takeaways from the Metastatic Breast Cancer Pipeline Report

• In October 2024:- Merck Sharp & Dohme LLC- The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician’s Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer.
• In October 2024:- Novartis Pharmaceuticals- The purpose of this study is to evaluate long-term safety and provide continued treatment to participants who are currently receiving ribociclib in combination with other drugs in a parent study, that has fulfilled requirements for its primary objective(s), and in the opinion of the Investigator, would benefit from continuing treatment at time of discontinuation from the parent study
• In October 2024:- UNICANCER-This study is a randomized, open-label, multicentric, phase III trial conducted in patients receiving aromatase inhibitor and palbociclib as first line therapy for estrogen receptor (ER)-positive HER2-negative metastatic breast cancer and which aims to evaluate, at the onset of ESR1 mutations in circulating tumor DNA, the efficacy of a change of the hormone therapy (aromatase inhibitor (AI) changed to fulvestrant) combined to palbociclib, together with the safety of hormone therapy and palbociclib combination in the overall population.
• In October 2024:- Hoffmann-La Roche-A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer. This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after induction therapy in participants with previously untreated HER2-positive advanced breast cancer (ABC).
• In October 2024:- Sermonix Pharmaceuticals- An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation
• In October 2024:-AstraZeneca- A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With HER2-positive Metastatic Breast Cancer (DESTINY-Breast07). DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer
• In October 2024:- BriaCell Therapeutics Corporation- This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients’/Physicians’ Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.
• In October 2024:- Eli Lilly and Company- The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaciclib work compared to imlunestrant in participants with breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have breast cancer that is advanced or has spread to another part of the body. Study participation could last up to 5 years.
• In October 2024:- Sanofi- The duration of the study for an individual participant will include a period to assess eligibility (screening period) of up to 4 weeks (28 days), a treatment period of at least 1 cycle (28 days of study treatment), and an end of treatment (EOT) visit at least 30 days (or until the participant receive another anticancer therapy, whichever is earlier) following the last administration of study treatment. Study treatment may continue until precluded by unacceptable toxicity, disease progression, death or upon participant’s request to stop treatment, or Investigator decision, whichever occurs first.
• DelveInsight’s Metastatic Breast Cancer pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Metastatic Breast Cancer treatment.
• The leading Metastatic Breast Cancer Companies working in the market include Roche, RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, GlycoMimetics Incorporated, Rhizen Pharmaceuticals SA, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd., Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, Jiangsu Hengrui Medicine Co., Tyme, Inc., Orion Pharma, HiberCell, Inc., Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, OncoPep Inc., and Taizhou Hanzhong biomedical co. Ltd, and others.
• Promising Metastatic Breast Cancer therapies in the various stages of development include Tucatinib, Capecitabine, Trastuzumab, Palifosfamide, Bavituximab, NK105, Paclitaxel, Navelbine, Herceptin, and others

Stay informed about the cutting-edge advancements in Metastatic Breast Cancer treatments. Download for updates and be a part of the revolution in care @ Metastatic Breast Cancer Clinical Trials Assessment

Metastatic Breast Cancer Emerging Drugs Profile

• Giredestrant: Roche

Giredestrant is a next generation investigational Selective estrogen receptor degrader (SERD), designed to fully block ER signalling with robust receptor occupancy. Oestrogen encourages HR-positive breast cancer cells to grow by attaching to the ER. Giredestrant works by blocking this receptor to prevent the action of oestrogen, and in the process causes the receptor to be degraded. This investigational medicine has also shown efficacy regardless of ESR1 mutation status (mutations in the ESR1 gene are important mechanisms of resistance to hormone therapy).

• Disitamab Vedotin: RemeGen

Disitamab Vedotin (RC48) is a novel anti-HER2 antibody-drug conjugate (ADC) which is currently across various solid tumor types. It was the first domestically-developed ADC in China approved by the CDE for clinical development in China. ADCs are a therapeutic modality consisting of an antibody molecule linked to a highly cytotoxic agent, and is typically designed to specifically deliver chemotherapies to tumor cells.

• EndoTAG®-1 (SB05): SynCore Biotechnology

SB05 is an innovative composition of the established cytostatic drug paclitaxel combined with neutral and positive lipids. Due to the positively charged lipids, SB05 interacts with newly developing, negatively charged endothelial cells, which are especially required for the growth of tumor blood vessels. The SB05 paclitaxel component attacks the activated endothelial cells as they divide, thus targeting the blood supply to tumors without affecting the supply to not activated endothelial cells of healthy tissue. By doing this, SB05 is expected to prevent the formation of new tumor blood vessels and to inhibit tumor growth.

• Stenoparib (2X-121): Allarity Therapeutics

Stenoparib (2X-121) is a unique, small molecule dual targeted inhibitor of Poly ADP-Ribose Polymerases (PARP 1 and 2) and telomerase maintenance enzymes (Tankyrase 1 and 2). Allarity exclusively in-licensed it (globally) from Eisai. Given its novel mechanism of action and ability to cross the blood brain barrier (BBB), plus its associated DRP®, stenoparib is poised to yield improved efficacy, lower toxicity, and lower drug resistance compared the other late-stage or marketed PARP inhibitors.

Learn more about Metastatic Breast Cancer Drugs opportunities in our groundbreaking Metastatic Breast Cancer Research and development projects @ Metastatic Breast Cancer Unmet Needs

Metastatic Breast Cancer Companies

Roche, RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, GlycoMimetics Incorporated, Rhizen Pharmaceuticals SA, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd., Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, Jiangsu Hengrui Medicine Co., Tyme, Inc., Orion Pharma, HiberCell, Inc., Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, OncoPep Inc., and Taizhou Hanzhong biomedical co. Ltd, and others.

Metastatic Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Metastatic Breast Cancer Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Discover the latest advancements in Metastatic Breast Cancer treatment by visiting our website. Stay informed about how we’re transforming the future of disease @ Metastatic Breast Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Metastatic Breast Cancer Pipeline Report

• Coverage- Global
• Metastatic Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Metastatic Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Metastatic Breast Cancer Companies- Roche, RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, GlycoMimetics Incorporated, Rhizen Pharmaceuticals SA, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd., Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, Jiangsu Hengrui Medicine Co., Tyme, Inc., Orion Pharma, HiberCell, Inc., Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, OncoPep Inc., and Taizhou Hanzhong biomedical co. Ltd, and others.
• Metastatic Breast Cancer Therapies- Tucatinib, Capecitabine, Trastuzumab, Palifosfamide, Bavituximab, NK105, Paclitaxel, Navelbine, Herceptin, and others.

For a detailed overview of our latest research findings and future plans, read the full details of Metastatic Breast Cancer Pipeline on our website @ Metastatic Breast Cancer Emerging Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Metastatic Breast Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Metastatic Breast Cancer – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Giredestrant: Roche
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Stenoparib – Allarity Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. ARV-471: Arvinas
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Metastatic Breast Cancer Key Companies
21. Metastatic Breast Cancer Key Products
22. Metastatic Breast Cancer- Unmet Needs
23. Metastatic Breast Cancer- Market Drivers and Barriers
24. Metastatic Breast Cancer- Future Perspectives and Conclusion
25. Metastatic Breast Cancer Analyst Views
26. Metastatic Breast Cancer Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Breast Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

DelveInsight’s, “Pancreatic Ductal Adenocarcinoma Pipeline Insight” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Pancreatic Ductal Adenocarcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Pancreatic Ductal Adenocarcinoma Research. Learn more about our innovative pipeline today! @ Pancreatic Ductal Adenocarcinoma Pipeline Outlook

Key Takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report

• In October 2024:- Debiopharma International SA- A Multicenter, Open-Label, Non-Randomized Phase 1/2 Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga] Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Patients With Unresectable Locally Advanced or Metastatic Solid Tumors. The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of [68Ga]Ga-DPI-4452 for each tumor type; Part B: is to determine the recommended phase 2 dose (RP2D) [maximum tolerated dose (MTD) or lower dose] for [177Lu]Lu-DPI-4452 for each tumor type; Part C: is to evaluate the preliminary antitumor activity of [177Lu]Lu-DPI-4452 as monotherapy.
• In October 2024:- Boehringer Ingelheim- The purpose of this study is to find out whether a medicine called BI 907828 helps people with cancer in the biliary tract, pancreas, lung, or bladder. BI 907828 is a so-called MDM2 inhibitor that is being developed to treat cancer. All participants take BI 907828 as a tablet once every 3 weeks. Participants may continue to take BI 907828 as long as they benefit from treatment and can tolerate it. They visit the study site regularly. At the study site, doctors regularly check the size of the tumour and whether it has spread to other parts of the body. The doctors also regularly check participants’ health and take note of any unwanted effects.
• In October 2024:- Trishula Therapeutics Inc.- This is a Phase 2, multicenter, open-label, 3-arm, randomized, parallel group study to evaluate the efficacy and safety of TTX-030 with or without budigalimab in combination with chemotherapy (gemcitabine + nab-paclitaxel) in subjects with metastatic PDAC who did not have prior treatment for metastatic disease and are eligible to receive gemcitabine and nab-paclitaxel chemotherapy as SOC.
• In October 2024:-  AstraZeneca- A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T Cell-engaging Bispecific Antibody That Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants with Advanced or Metastatic Solid Tumors. This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.
• In October 2024:- Merck Sharp & Dohme LLC- A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers. Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with chemotherapy can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surgery).
• In October 2024:- Revolution Medicines Inc.- The platform study design allows combinations of RAS(ON) inhibitors with other anticancer agents to be evaluated in patients with RAS-mutated solid tumors with a focus on GI cancers. This is an open-label platform study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard of Care (SOC) or with novel agents, and to define the Recommended Phase 2 Dose and Schedule (RP2DS). Enrollment of patients with RAS mutations will be specified in each subprotocol.
• In October 2024:- Lisata Therapeutics Inc.- This is a Phase 1b/2a, double-blind, placebo-controlled, three-arm, randomized study evaluating continuous infusion of LSTA1 over 4 hours when added to standard of care (SoC) versus a single intravenous push of LSTA1 when added to SoC, versus SoC alone in people with metastatic pancreatic ductal adenocarcinoma (mPDAC) who have progressed on FOLFIRINOX. The study will consist of a screening period, a run-in period, a treatment period, an end-of-treatment follow-up visit, and a long-term follow up period.
• In October 2024:- Akeso- This trial is a Phase Ib/II study. All patients are stage IV pancreatic cancer (PDAC) patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. The purpose of this study is to evaluate the safety and efficacy of AK112 and Cadonilimab combined with chemotherapy as first-line treatment for patients with metastatic pancreatic cancer.
• In October 2024- Genentech Inc.- The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.
• DelveInsight’s Pancreatic Ductal Adenocarcinoma pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Pancreatic Ductal Adenocarcinoma treatment.
• The leading Pancreatic Ductal Adenocarcinoma Companies such as Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, Tarveda Therapeutics, and others.
• Promising Pancreatic Ductal Adenocarcinoma Therapies such as Zimberelimab, Quemliclustat, Onvansertib, Nanoliposomal irinotecan, Leucovorin, mFOLFIRINOX, and others.

Stay informed about the cutting-edge advancements in Pancreatic Ductal Adenocarcinoma Treatments. Download for updates and be a part of the revolution in oncology care @ Pancreatic Ductal Adenocarcinoma Clinical Trials Assessment

Pancreatic Ductal Adenocarcinoma Emerging Drugs Profile

• Onvansertib: Cardiff Oncology

Onvansertib, an oral highly-selective PLK1 inhibitor, which we are evaluating in combination with standard-of-care (SOC) therapeutics in clinical programs targeting indications such as KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SOC.

• Nadunolimab: Cantargia

Nadunolimab is a humanised monoclonal antibody lacking fucose, being developed by Cantargia, for the treatment of solid tumours, including non-small cell lung cancer (NSCLC) and pancreatic cancer. Nadunolimab is a first-in-class anti-IL1RAP antibody, currently evaluated with standard of care chemotherapy or checkpoint inhibitor in five phase I/II clinical trials with a primary focus on PDAC and NSCLC. Nadunolimab induces ADCC and blocks signaling of both IL-1α and IL-1β, counteracting thecontribution of IL-1 to the immune suppressive tumor microenvironment and development of resistance to chemotherapy

• Zimberelimab: Arcus Biosciences

Zimberelimab is a monoclonal antibody that binds pd-1 restoring the antitumor activity of T-cells. Zimberelimab was in-licensed by Arcus to enable the development of precision combination regimens with The most advanced study with zimberelimab is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer, evaluating zimberelimab in combination with domvanalimab, an anti-TIGIT monoclonal antibody, and etrumadenant, the first and only dual A2a/A2b adenosine receptor antagonist in the clinic. Zimberelimab is also being evaluated as monotherapy in a tumor agnostic, biomarker-selected Phase 1b trial for cancers with no approved anti-PD-1 treatment options. full line-of-sight to the commercialization of innovative therapies for all patients who may benefit.

Learn more about Pancreatic Ductal Adenocarcinoma Drugs opportunities in our groundbreaking A Pancreatic Ductal Adenocarcinoma Research and development projects @ Pancreatic Ductal Adenocarcinoma Unmet Needs

Pancreatic Ductal Adenocarcinoma Companies

Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, Tarveda Therapeutics, and others.

Pancreatic Ductal Adenocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

• Oral
• Intravenous
• Subcutaneous

Pancreatic Ductal Adenocarcinoma Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Discover the latest advancements in Pancreatic Ductal Adenocarcinoma Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology disease @ Pancreatic Ductal Adenocarcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Pancreatic Ductal Adenocarcinoma Pipeline Report

• Coverage- Global
• Pancreatic Ductal Adenocarcinoma Companies- Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, Tarveda Therapeutics, and others.
• Pancreatic Ductal Adenocarcinoma Therapies- Zimberelimab, Quemliclustat, Onvansertib, Nanoliposomal irinotecan, Leucovorin, mFOLFIRINOX, and others.
• Pancreatic Ductal Adenocarcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Pancreatic Ductal Adenocarcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Pancreatic Ductal Adenocarcinoma Pipeline on our website @ Pancreatic Ductal Adenocarcinoma Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Pancreatic Ductal Adenocarcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Pancreatic Ductal Adenocarcinoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. NIS 793: XOMA
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. CEND 1: Cend Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. DCC-3116: Deciphera Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. RMC-6236: REVOLUTION Medicines
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Pancreatic Ductal Adenocarcinoma Key Companies
21. Pancreatic Ductal Adenocarcinoma Key Products
22. Pancreatic Ductal Adenocarcinoma- Unmet Needs
23. Pancreatic Ductal Adenocarcinoma- Market Drivers and Barriers
24. Pancreatic Ductal Adenocarcinoma- Future Perspectives and Conclusion
25. Pancreatic Ductal Adenocarcinoma Analyst Views
26. Pancreatic Ductal Adenocarcinoma Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

DelveInsight’s, “Paroxysmal Nocturnal Haemoglobinuria Pipeline Insight 2024” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Paroxysmal Nocturnal Haemoglobinuria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Paroxysmal Nocturnal Hemoglobinuria Research. Learn more about our innovative pipeline today! @ Paroxysmal Nocturnal Hemoglobinuria Pipeline Outlook

Key Takeaways from the Paroxysmal Nocturnal Hemoglobinuria Pipeline Report

• In October 2024:- Alexion Pharmaceuticals- A Phase 3, Single-arm, Open-label, Multicenter Study to Assess the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Complement Inhibitor Treatment Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China. The primary objective of this study is to evaluate the efficacy of ravulizumab in adult participants with PNH.
• In October 2024:- Hoffmann-La Roche- A Phase III, Randomized, Open-Label, Active-Controlled, Multicenter Study Evaluating The Safety, Pharmacokinetics, Pharmacodynamic And Efficacy of Crovalimab Versus Eculizumab In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors. A study designed to evaluate the safety of crovalimab with eculizumab in participants with PNH currently treated with complement inhibitors. This study will enroll approximately 190 participants.
• In October 2024:- Kira Pharmacenticals (US), LLC- The purpose of this study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of KP104 in complement inhibitor-naïve participants with PNH. The study will be conducted in 2 parts. Part 1 is a dose-selection study to assess escalating doses and varying dose intervals of KP104. Part 2 is a proof-of-concept (POC) study assessing the efficacy of the optimal intravenous (IV) loading dose followed by the optimal maintenance dose and regimen of KP104. Participants who complete the Initial Treatment Period and demonstrate benefit from KP104 will be eligible for a 9-month open-label extension (OLE) treatment period.
• In October 2024:- Regeneron Pharmaceuticals- This study is researching an experimental treatment combination with two experimental drugs called pozelimab and cemdisiran. The study is focused on patients with paroxysmal nocturnal hemoglobinuria (PNH). The aim of this study is to see how safe and effective the pozelimab + cemdisiran combination is for patients with PNH in the long term. The pozelimab + cemdisiran combination may be referred to as “study drugs” in this section.
• In October 2024:- Novartis Pharmaceuticals- The purpose of this phase 3 open-label, single arm, multicenter study is to evaluate the long-term safety, tolerability and efficacy of iptacopan in patients with PNH and to provide access to patients who have completed (without tapering down) Phase 2 and Phase 3 trials and derived benefit from iptacopan treatment.
• DelveInsight’s Paroxysmal Nocturnal Hemoglobinuria pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Paroxysmal Nocturnal Hemoglobinuria treatment.
• The leading Paroxysmal Nocturnal Hemoglobinuria Companies such as Hoffmann-La Roche, Apellis Pharmaceuticals, Regeneron Pharmaceuticals, Biocad, AKARI Therapeutics, Alexion Pharmaceuticals, Novartis Pharmaceuticals, Amgen, BioCryst Pharmaceuticals, MorphoSys, Ra Pharmaceuticals, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Wuhan Createrna Science and Technology, CANbridge, Attune Pharmaceuticals, RallyBio, and others.
• Promising Paroxysmal Nocturnal Hemoglobinuria Therapies such as Eculizumab, BCX9930, Crovalimab, HRS-5965 tablets, Iptacopan, vMY008211A tablets, Pozelimab, Cemdisiran, KP104, Eculizumab, and others.

Stay informed about the cutting-edge advancements in Paroxysmal Nocturnal Hemoglobinuria treatments. Download for updates and be a part of the revolution in care @ Paroxysmal Nocturnal Hemoglobinuria Clinical Trials Assessment

Paroxysmal Nocturnal Hemoglobinuria Emerging Drugs Profile

• Crovalimab: Hoffman-La-Roche

Crovalimab (RG6107) is a humanised complement inhibitor C5 monoclonal antibody discovered by Chugai using recycling antibody technology. By blocking the cleavage of C5 to C5a and C5b, it is expected to inhibit complement activation, which is the cause of a number of diseases. As the complement system is a key innate immune defense mechanism, we plan to study the potential of this antibody in a broader range of complement-mediated diseases. A phase III clinical trial is evaluating crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria.

• Pozelimab: Regeneron Pharmaceuticals

Pozelimab is an investigational, fully-human monoclonal antibody designed to block complement factor C5 and prevent the destruction of red blood cells (hemolysis) that cause the symptoms of PNH and other diseases mediated by complement pathway activity. It is an IgG4 antibody that binds with high affinity to wild-type and variant human C5 and blocks its activity. Pozelimab was invented using Regeneron’s proprietary VelocImmune technology, which uses a unique genetically-humanized mouse to produce optimized fully-human antibodies. Pozelimab is currently under clinical development, and its safety and efficacy have not been evaluated by any regulatory authority.

Learn more about Paroxysmal Nocturnal Hemoglobinuria Drugs opportunities in our groundbreaking Asthma Research and development projects @ Paroxysmal Nocturnal Hemoglobinuria Unmet Needs

Paroxysmal Nocturnal Hemoglobinuria Companies

Hoffmann-La Roche, Apellis Pharmaceuticals, Regeneron Pharmaceuticals, Biocad, AKARI Therapeutics, Alexion Pharmaceuticals, Novartis Pharmaceuticals, Amgen, BioCryst Pharmaceuticals, MorphoSys, Ra Pharmaceuticals, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Wuhan Createrna Science and Technology, CANbridge, Attune Pharmaceuticals, RallyBio, and others.

Paroxysmal Nocturnal Haemoglobinuria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Paroxysmal Nocturnal Hemoglobinuria Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Discover the latest advancements in Paroxysmal Nocturnal Hemoglobinuria treatment by visiting our website. Stay informed about how we’re transforming the future of disease @ Paroxysmal Nocturnal Hemoglobinuria Market Drivers and Barriers, and Future Perspectives

Scope of the Paroxysmal Nocturnal Hemoglobinuria Pipeline Report

• Coverage- Global
• Paroxysmal Nocturnal Hemoglobinuria Companies- Hoffmann-La Roche, Apellis Pharmaceuticals, Regeneron Pharmaceuticals, Biocad, AKARI Therapeutics, Alexion Pharmaceuticals, Novartis Pharmaceuticals, Amgen, BioCryst Pharmaceuticals, MorphoSys, Ra Pharmaceuticals, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Wuhan Createrna Science and Technology, CANbridge, Attune Pharmaceuticals, RallyBio, and others.
• Paroxysmal Nocturnal Hemoglobinuria Therapies- Eculizumab, BCX9930, Crovalimab, HRS-5965 tablets, Iptacopan, vMY008211A tablets, Pozelimab, Cemdisiran, KP104, Eculizumab, and others.
• Paroxysmal Nocturnal Hemoglobinuria Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Paroxysmal Nocturnal Hemoglobinuria Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Paroxysmal Nocturnal Hemoglobinuria Pipeline on our website @ Paroxysmal Nocturnal Hemoglobinuria Emerging Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Paroxysmal Nocturnal Haemoglobinuria: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Paroxysmal Nocturnal Haemoglobinuria – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Paroxysmal Nocturnal Haemoglobinuria Collaboration Deals
9. Late Stage Products (Phase III)
10. Crovalimab: Hoffman-La-Roche
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. BCX9930: BioCryst pharmaceuticals
14. Drug profiles in the detailed report…..
15. Eary Stage Products (Phase I)
16. CAN106: CanBridge
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Paroxysmal Nocturnal Haemoglobinuria Key Companies
20. Paroxysmal Nocturnal Haemoglobinuria Key Products
21. Paroxysmal Nocturnal Haemoglobinuria- Unmet Needs
22. Paroxysmal Nocturnal Haemoglobinuria- Market Drivers and Barriers
23. Paroxysmal Nocturnal Haemoglobinuria- Future Perspectives and Conclusion
24. Paroxysmal Nocturnal Haemoglobinuria Analyst Views
25. Paroxysmal Nocturnal Haemoglobinuria Key Companies
26. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Paroxysmal Nocturnal Hemoglobinuria Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

DelveInsight’s, “Janus Kinase Inhibitor Pipeline Insight 2024” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Janus Kinase (JAK) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Janus Kinase Inhibitor Research. Learn more about our innovative pipeline today! @ Janus Kinase Inhibitor Pipeline Outlook

Key Takeaways from the Janus Kinase Inhibitor Pipeline Report

• In October 2024:- Kartos Therapeutics Inc.- A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib Vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib. This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone.
• In October 2024:- Pfizer- This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata. Eligible patients from the prior studies B7931005 (NCT02974868) and B7981015 (NCT03732807) will have an opportunity to enroll as well as patients who have not previously participated in either of these studies. The study is open-label and all patients entering the study will receive active study drug.
• In October 2024:- Incyte Corporation- A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis. This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
• In October 2024:- Sanofi- A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment.
• In October 2024:- Geron Corporation- The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory to Janus Kinase (JAK)-Inhibitor treatment.
• DelveInsight’s Janus Kinase Inhibitor pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Janus Kinase Inhibitor treatment.
• The leading Janus Kinase Inhibitor Companies such as Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Incyte Corporation, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Celon Pharma, Incyte Corporation, Arcutis, Biotherapeutics/Reistone Biopharma, and others.
• Promising Janus Kinase Inhibitor Therapies such as Abrocitinib 200 MG Oral Tablet, Ritlecitinib, TL-895, KRT-232, Selinexor 60 mg, Navtemadlin, Ruxolitinib, Imetelstat, and others.

Stay informed about the cutting-edge advancements in Janus Kinase Inhibitor treatments. Download for updates and be a part of the revolution in care @ Janus Kinase Inhibitor Clinical Trials Assessment

Janus Kinase Inhibitor Emerging Drugs Profile

• Povorcitinib: Incyte Corporation

Povorcitinib (INCB054707) is an oral small-molecule JAK1 inhibitor. The chemical structure for povorcitinib was revealed in WHO proposed INN list 126 (Jan 2022), in which it was described as a Janus kinase inhibitor and anti-inflammatory agent. The drug is also being evaluated in Phase II clinical trials for Prurigo Nodularis, and others. Currently, the drug is in Phase III stage of its development for the treatment of Hidradenitis suppurativa, vitiligo.

• CPL409116: Celon Pharma

CPL 409116 is the first in class dual JAK/ROCK inhibitor in clinical development and is designed to generate anti-inflammatory and anti-fibrotic effects in selected autoimmune diseases. CPL’116 was administered orally in single ascending doses in healthy volunteers in order to assess safety and pharmacokinetic parameters (PK). No adverse events associated with administration of the investigational drug were observed, and the trial met its primary endpoint. Currently the drug is in Phase II stage of development for autoimmune indications including in patients with rheumatoid arthritis with coexisting interstitial lung disease.

• ATI-2138: Aclaris Therapeutics

ATI-2138 is an investigational oral covalent ITK/JAK3 inhibitor that is being developed as a potential therapeutic option across a variety of T cell-mediated diseases. ITK is a T cell receptor activated kinase involved in driving T cell effector functions while JAK3 is a non-receptor tyrosine kinase responsible for the signal transduction of common gamma receptor cytokines, IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. In blocking both T cell receptor function and cytokine signaling, ATI-2138 has potential utility in T cell driven diseases. ATI-2138 is currently in clinical development and its safety and efficacy has not been evaluated by regulatory authorities.

• SDC 1802: Sareum

SDC-1802 is an investigational Sareum’s TYK2/JAK1 preclinical development candidate molecule that demonstrates high selectivity for TYK2 and JAK1 kinases (particularly over related JAK2 and JAK3). SDC-1802 shows compelling efficacy in blocking cancer cell proliferation in cellular and disease models of T-cell acute lymphoblastic leukaemia (T-ALL) and B-cell lymphoma, the potential for once-daily oral dosing and a good early safety profile. Sareum is progressing SDC-1802 through preclinical development and pending satisfactory progress, into human clinical trials. SDC-1802 has the potential to act as a back-up molecule for these autoimmune indications. Currently, the drug is in Preclinical stage of its development for the treatment of cancer.

Learn more about Janus Kinase Inhibitor Drugs opportunities in our groundbreaking Janus Kinase Inhibitor Research and development projects @ Janus Kinase Inhibitor Unmet Needs

Janus Kinase Inhibitor Companies

Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Incyte Corporation, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Celon Pharma, Incyte Corporation, Arcutis, Biotherapeutics/Reistone Biopharma, and others.

Janus Kinase (JAK) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Janus Kinase Inhibitor Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Janus Kinase Inhibitor treatment by visiting our website. Stay informed about how we’re transforming the future of disease @ Janus Kinase Inhibitor Market Drivers and Barriers, and Future Perspectives

Scope of the Janus Kinase Inhibitor Pipeline Report

• Coverage- Global
• Janus Kinase Inhibitor Companies- Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Incyte Corporation, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Celon Pharma, Incyte Corporation, Arcutis, Biotherapeutics/Reistone Biopharma, and others.
• Janus Kinase Inhibitor Therapies- Abrocitinib 200 MG Oral Tablet, Ritlecitinib, TL-895, KRT-232, Selinexor 60 mg, Navtemadlin, Ruxolitinib, Imetelstat, and others.
• Janus Kinase Inhibitor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Janus Kinase Inhibitor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Janus Kinase Inhibitor Pipeline on our website @ Janus Kinase Inhibitor Emerging Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Janus Kinase (JAK) Inhibitor: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Janus Kinase (JAK) Inhibitor– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Povorcitinib: Incyte Corporation
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. CPL409116: Celon Pharma
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ATI-2138: Aclaris Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. SDC 1802: Sareum
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Janus Kinase (JAK) Inhibitor Key Companies
21. Janus Kinase (JAK) Inhibitor Key Products
22. Janus Kinase (JAK) Inhibitor- Unmet Needs
23. Janus Kinase (JAK) Inhibitor- Market Drivers and Barriers
24. Janus Kinase (JAK) Inhibitor- Future Perspectives and Conclusion
25. Janus Kinase (JAK) Inhibitor Analyst Views
26. Janus Kinase (JAK) Inhibitor Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Janus Kinase Inhibitor Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

DelveInsight’s, “Myelofibrosis Pipeline Insight 2024” report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in Myelofibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Myelofibrosis Research. Learn more about our innovative pipeline today! @ Myelofibrosis Pipeline Outlook

Key Takeaways from the Myelofibrosis Pipeline Report

• In October 2024:- Swedish Orphan Biovitrum- This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician’s choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count <50,000/μL). Approximately 399 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 266 patients) or to P/C therapy (approximately 133 patients)
• In October 2024:- Constellation Pharmaceuticals- A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been previously treated with Janus kinase inhibitors (JAKi). Pelabresib is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
• In October 2024:- Incyte Corporation- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kδ Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis. The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.
• In October 2024:- Celgene- This is a Phase 1/2 multicenter, single arm, open-label study in Japanese subjects with DIPSS intermediate or high-risk PMF, post-PV or post-ET MF. The study consists of 2 parts: Phase 1 part to determine safety and tolerability and a RP2D. The Phase 1 portion of the study will explore one or more drug doses for fedratinib (300 mg and 400 mg) using a mTPI-2 design. Following completion of dose escalation and determination of MTD and/or a RP2D, the study will progress into the Phase 2 part to further evaluate the efficacy and safety.
• In October 2024:- Geron Corporation- The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory to Janus Kinase (JAK)-Inhibitor treatment.
• In October 2024:- Ryvu Therapeutics SA- The objective of this clinical trial is to evaluate the efficacy (how well the drug works), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the study drug, RVU120, in treating adult patients with intermediate or high-risk, primary or secondary myelofibrosis. RVU120 will be given as a single agent or in combination with ruxolitinib.
• DelveInsight’s Myelofibrosis pipeline report depicts a robust space with 35+ active players working to develop 40+ pipeline therapies for Myelofibrosis treatment.
• The leading Myelofibrosis Companies such as Geron Corporation, Merck, Telios Pharma Inc., Ryvu Therapeutics SA, Taiga Biotechnologies, Inc., Morphic Therapeutic, iOnctura, Pharmaxis, Nippon Shinyaku, Active Biotech, Incyte Corporation, Sumitomo Pharma America, Inc., and others.
• Promising Myelofibrosis Therapies such as Momelotinib, Luspatercept, Bomedemstat, Pacritinib, RVU120, Ruxolitinib, and others.

Stay informed about the cutting-edge advancements in Myelofibrosis treatments. Download for updates and be a part of the revolution in care @ Myelofibrosis Clinical Trials Assessment

Myelofibrosis Emerging Drugs Profile

• Imetelstat: Geron Corporation

Imetelstat sodium (imetelstat) is a small oligonucleotide composed of a nucleic acid and a lipid moiety. The proprietary nucleic acid backbone provides resistance to degradation, thus conferring improved stability in plasma and tissues, as well as significantly improved binding affinity to its target. The lipid group enhances cell permeability, which results in increased potency and improved pharmacokinetic and pharmacodynamic properties. The compound has a long residence time in bone marrow, spleen, and liver. Imetelstat binds with high affinity to the template region of the RNA component of telomerase, resulting in direct, competitive inhibition of telomerase enzymatic activity rather than eliciting its effect through an antisense inhibition of protein translation. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Myelofibrosis.

• Bomedemstat: Merck

Bomedemstat is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1), an enzyme critical for regulating the proliferation of hematopoietic stem cells and the maturation of progenitors. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Myelofibrosis.

• TL-895: Telios Pharma, Inc.

It is an orally bioavailable inhibitor of tyrosine kinase, with potential anti-inflammatory and antineoplastic activities. Upon oral administration, tyrosine kinase inhibitor TL-895 targets, binds to, and inhibits tyrosine kinase. This may result in the inhibition of tumor angiogenesis and cell proliferation, and the inhibition of immune-mediated inflammatory processes. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Myelofibrosis.

• RVU120: Ryvu Therapeutics SA

RVU120 is a selective, first-in-class dual CDK8/19 kinase inhibitor developed by Ryvu Therapeutics. RVU120’s mechanism of action (MoA) involves targeting CDK8/19 kinases. Specifically, translational data confirm the proposed MoA in a molecularly-defined subset of patients with DNMT3A and NPM1 mutations. Currently, the drug is in the Phase II stage of development to treat Myelofibrosis.

• TBX-2400: Taiga Biotechnologies, Inc.

TBX-2400 is an allogeneic stem cell therapy developed by Taiga Biotechnologies that aims to improve the rate of engraftment and reconstitution of the immune system for patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Currently, the drug is in the Phase I stage of development to treat Myelofibrosis.

Learn more about Myelofibrosis Drugs opportunities in our groundbreaking Myelofibrosis Research and development projects @ Myelofibrosis Unmet Needs

Myelofibrosis Companies

Geron Corporation, Merck, Telios Pharma Inc., Ryvu Therapeutics SA, Taiga Biotechnologies, Inc., Morphic Therapeutic, iOnctura, Pharmaxis, Nippon Shinyaku, Active Biotech, Incyte Corporation, Sumitomo Pharma America, Inc., and others.

Myelofibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Myelofibrosis Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Myelofibrosis treatment by visiting our website. Stay informed about how we’re transforming the future of disease @ Myelofibrosis Market Drivers and Barriers, and Future Perspectives

Scope of the Myelofibrosis Pipeline Report

• Coverage- Global
• Myelofibrosis Companies- Geron Corporation, Merck, Telios Pharma Inc., Ryvu Therapeutics SA, Taiga Biotechnologies, Inc., Morphic Therapeutic, iOnctura, Pharmaxis, Nippon Shinyaku, Active Biotech, Incyte Corporation, Sumitomo Pharma America, Inc., and others.
• Myelofibrosis Therapies- Momelotinib, Luspatercept, Bomedemstat, Pacritinib, RVU120, Ruxolitinib, and others.
• Myelofibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Myelofibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Myelofibrosis Pipeline on our website @ Myelofibrosis Emerging Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Myelofibrosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Myelofibrosis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Imetelstat: Geron Corporation
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. RVU120: Ryvu Therapeutics SA
12. Drug profiles in the detailed report…..
13. TBX-2400: Taiga Biotechnologies, Inc.
14. Drug profiles in the detailed report…..
15. Preclinical and Discovery Stage Products
16. Drug name: Company name
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Myelofibrosis Key Companies
20. Myelofibrosis Key Products
21. Myelofibrosis- Unmet Needs
22. Myelofibrosis- Market Drivers and Barriers
23. Myelofibrosis- Future Perspectives and Conclusion
24. Myelofibrosis Analyst Views
25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Myelofibrosis Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers